UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, ...

UVA scientists discovered a molecule that blocks a key gene that drives glioblastoma, offering hope for a new treatment ...

As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma ...

COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role. However, current ICIs, primarily monoclonal antibodies, face significant challenges ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...

A team of researchers at Broad Institute of MIT and Harvard, in a long-term project that has included industry collaborators at Bayer and Trueline Therapeutics, has developed a compound called BRD-810 ...

Small Molecule Drug Development Core Facility (SMDD Core) has the automation equipment, libraries, and experienced personnel to support a wide range of assay ...

Deerfield Management, Khosla Ventures, and Sofinnova Partners co-lead Series A fundraise for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring.

Recent research highlights an approach in cancer therapy with small molecule drugs targeting immune checkpoints. These innovative drugs overcome the limitations of antibody-based inhibitors, such as ...